In metastatic melanoma cells, decreased TFAP2A changes the binding ratio of TFAP2A/SP1 on the protease-activated receptor-1 (PAR1) promoter, which results in overexpression of PAR1 and promotes tumor oncogenesis and malignancy [15]. Here, MARK2 is linked to neoplasm.